UPDATE of NEW RESULTS, PROGRESS and FUTURE PLANSMonday 05-Sep-2022 12:00 – 14:00 GMTPlease contact email@example.com to register for the on-line meeting ...
STAMPEDE Trial Further Results - Adding Radiotherapy Can Benefit Some Patients Whose Prostate Cancer Has Spread
Adding radiotherapy to standard hormone therapy helps patients with prostate cancer with limited spread of the disease, to live longer. This result from the STAMPEDE trial was published, in open access format, in the PLOS Medicine journal, in early June. For more on this story, please click on the following link to the UCL News feed: https://www.mrcctu.ucl.ac.uk/news/news-stories/2022/june/adding-radiotherapy-can-benefit-some-patients-whose-prostate-cancer-has-spread/ ...
STAMPEDE Five Year Follow-up Results
A five year follow-up of the STAMPEDE abiraterone comparison has been completed, and the results demonstrate that previously reported effects are robust. It shows that future results are unlikely to change meaningfully with further follow-up. The initial results of the STAMPEDE advanced prostate cancer trial showed that progression-free survival is improved when abiraterone acetate and prednisone (AAP) are added to androgen deprivation therapy. For further details related to the follow-up results, please see this article published 12th April 2022 - https://onlinelibrary.wiley.com/doi/10.1002/ijc.34018 ...
MRC Clinical Trials Unit at UCL
90 High Holborn